Ikonisys S.A.
ISIN: FR00140048X2 | Ticker: ALIKO
Ikonisys is transforming diagnostic medicine by enabling early, accurate and non-invasive disease detection. Through a unique combination of technology and science, Ikonisys is dedicated to helping physicians and researchers realize the promise of rare cell detection to give patients the best chance of managing their disease.
Through its breakthrough fluorescence microscopy platform, Ikonisys continues to develop a stream of oncology tests for a variety of cancers. At the center of the platform is the Ikoniscope20®, a robotic, high-throughput, microscopy system that provides a true “walk away” automated solution. In addition to providing high quality cell images, the platform analyzes the cells of interest, offering an interpretation of the analysis, to facilitate the quick, accurate reporting of the test result.
1999
Headquarters62 Rue de Caumartin, 75009 Paris – France
9,481,727
IPOJuly 19, 2021
Stock exchange(s)Euronext Paris